New vaccine trial aims to stop childhood brain tumors from growing

NCT ID NCT02358187

First seen Jan 10, 2026 · Last updated May 12, 2026 · Updated 21 times

Summary

This study tests a vaccine made from proteins found on glioma cells, combined with an immune booster, in children with low-grade gliomas that cannot be removed by surgery and have returned after at least two prior treatments. The goal is to see if the vaccine can shrink the tumor or keep it stable without serious side effects. Up to 25 children who have a specific immune marker (HLA-A2) will receive up to 8 initial vaccines, with extra doses possible for up to two years if the tumor responds.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOW GRADE GLIOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Children's Hospital of Pittsburgh of UPMC

    RECRUITING

    Pittsburgh, Pennsylvania, 15224, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.